What is he best known for?
The fields of study he is best known for:
- Gene
- Immune system
- Enzyme
The scientist’s investigation covers issues in Epitope, Major histocompatibility complex, Immunology, Cytotoxic T cell and Molecular biology.
His research integrates issues of Biochemistry, Peptide, Peptide sequence, Human leukocyte antigen and CTL* in his study of Epitope.
Major histocompatibility complex is a subfield of Antigen that he investigates.
His Immunology study incorporates themes from Transplantation and Graft-versus-host disease.
Victor H. Engelhard combines subjects such as Immune tolerance and Cell biology with his study of Cytotoxic T cell.
His Molecular biology study combines topics in areas such as Antigen processing, MHC class I, Antigen presentation, Transporter associated with antigen processing and Tyrosinase.
His most cited work include:
- Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry (1038 citations)
- Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines (794 citations)
- HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. (476 citations)
What are the main themes of his work throughout his whole career to date?
Victor H. Engelhard mainly focuses on Immunology, Cytotoxic T cell, Antigen, Major histocompatibility complex and Molecular biology.
His biological study spans a wide range of topics, including Cancer research, Virology and Cell biology.
His research in Antigen intersects with topics in Cancer, Phosphopeptide, Antigen presentation and T-cell receptor.
He has included themes like CD8 and Peptide in his Major histocompatibility complex study.
His Molecular biology study integrates concerns from other disciplines, such as Peptide sequence, Monoclonal antibody and Transporter associated with antigen processing.
The CTL* study which covers Epitope that intersects with Human leukocyte antigen and Minor histocompatibility antigen.
He most often published in these fields:
- Immunology (37.55%)
- Cytotoxic T cell (37.16%)
- Antigen (34.87%)
What were the highlights of his more recent work (between 2012-2021)?
- Immunology (37.55%)
- Cancer research (13.79%)
- T cell (17.24%)
In recent papers he was focusing on the following fields of study:
Immunology, Cancer research, T cell, Antigen and Immune system are his primary areas of study.
The study incorporates disciplines such as Phenotype, Internal medicine and Human melanoma in addition to Immunology.
His Cancer research research incorporates elements of Inflammation, Chemokine, Cytotoxic T cell and Cancer immunotherapy.
His Cytotoxic T cell research includes elements of Tumor microenvironment, CD8, Lymph node, Cell biology and Naive T cell.
His work in Major histocompatibility complex and Tolerance induction is related to Antigen.
His Major histocompatibility complex research integrates issues from Cancer cell and T-cell receptor.
Between 2012 and 2021, his most popular works were:
- MHC Class I–Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia (127 citations)
- Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity (104 citations)
- Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity (76 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Immune system
- Enzyme
Victor H. Engelhard focuses on Immunology, Cancer research, T cell, Major histocompatibility complex and Cytotoxic T cell.
The Cancer research study combines topics in areas such as Lymphatic system, Cancer immunotherapy, Immune system and Lymph.
Within one scientific family, he focuses on topics pertaining to Antigen under T cell, and may sometimes address concerns connected to Cell culture.
In his research, Molecular biology is intimately related to Antigen presentation, which falls under the overarching field of Cell culture.
He studies MHC class I, a branch of Major histocompatibility complex.
His Cytotoxic T cell research includes themes of Ipilimumab, Viral vector, Naive T cell and Vaccination.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
